Logo image of JANX

JANUX THERAPEUTICS INC (JANX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:JANX - US47103J1051 - Common Stock

14.31 USD
+0.19 (+1.35%)
Last: 12/24/2025, 7:40:10 PM
14.51 USD
+0.2 (+1.4%)
After Hours: 12/24/2025, 7:40:10 PM
Fundamental Rating

4

Overall JANX gets a fundamental rating of 4 out of 10. We evaluated JANX against 530 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for JANX as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, JANX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

JANX had negative earnings in the past year.
JANX had a negative operating cash flow in the past year.
JANX had negative earnings in each of the past 5 years.
JANX had a negative operating cash flow in each of the past 5 years.
JANX Yearly Net Income VS EBIT VS OCF VS FCFJANX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With an excellent Return On Assets value of -9.94%, JANX belongs to the best of the industry, outperforming 83.77% of the companies in the same industry.
JANX has a Return On Equity of -10.43%. This is amongst the best in the industry. JANX outperforms 87.17% of its industry peers.
Industry RankSector Rank
ROA -9.94%
ROE -10.43%
ROIC N/A
ROA(3y)-13.05%
ROA(5y)-17.92%
ROE(3y)-14.45%
ROE(5y)-29.83%
ROIC(3y)N/A
ROIC(5y)N/A
JANX Yearly ROA, ROE, ROICJANX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for JANX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JANX Yearly Profit, Operating, Gross MarginsJANX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

8

2. Health

2.1 Basic Checks

JANX does not have a ROIC to compare to the WACC, probably because it is not profitable.
JANX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, JANX has more shares outstanding
There is no outstanding debt for JANX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
JANX Yearly Shares OutstandingJANX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
JANX Yearly Total Debt VS Total AssetsJANX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

JANX has an Altman-Z score of 10.81. This indicates that JANX is financially healthy and has little risk of bankruptcy at the moment.
JANX has a Altman-Z score of 10.81. This is amongst the best in the industry. JANX outperforms 82.83% of its industry peers.
There is no outstanding debt for JANX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.81
ROIC/WACCN/A
WACC8.82%
JANX Yearly LT Debt VS Equity VS FCFJANX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

JANX has a Current Ratio of 35.86. This indicates that JANX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of JANX (35.86) is better than 98.87% of its industry peers.
JANX has a Quick Ratio of 35.86. This indicates that JANX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 35.86, JANX belongs to the best of the industry, outperforming 98.87% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 35.86
Quick Ratio 35.86
JANX Yearly Current Assets VS Current LiabilitesJANX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

JANX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -43.59%.
Looking at the last year, JANX shows a very negative growth in Revenue. The Revenue has decreased by -23.37% in the last year.
The Revenue has been growing by 42.75% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-43.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
Revenue 1Y (TTM)-23.37%
Revenue growth 3Y42.75%
Revenue growth 5YN/A
Sales Q2Q%2177.9%

3.2 Future

Based on estimates for the next years, JANX will show a very negative growth in Earnings Per Share. The EPS will decrease by -23.31% on average per year.
The Revenue is expected to grow by 74.85% on average over the next years. This is a very strong growth
EPS Next Y-59.85%
EPS Next 2Y-52.28%
EPS Next 3Y-43.94%
EPS Next 5Y-23.31%
Revenue Next Year-9.12%
Revenue Next 2Y-64.36%
Revenue Next 3Y-22.51%
Revenue Next 5Y74.85%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
JANX Yearly Revenue VS EstimatesJANX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
JANX Yearly EPS VS EstimatesJANX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

JANX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year JANX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JANX Price Earnings VS Forward Price EarningsJANX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JANX Per share dataJANX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

A cheap valuation may be justified as JANX's earnings are expected to decrease with -43.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-52.28%
EPS Next 3Y-43.94%

More info and screens

0

5. Dividend

5.1 Amount

JANX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

JANUX THERAPEUTICS INC

NASDAQ:JANX (12/24/2025, 7:40:10 PM)

After market: 14.51 +0.2 (+1.4%)

14.31

+0.19 (+1.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners106.72%
Inst Owner Change1.73%
Ins Owners1.45%
Ins Owner Change0%
Market Cap860.75M
Revenue(TTM)10.00M
Net Income(TTM)-101.89M
Analysts85.38
Price Target68.08 (375.75%)
Short Float %14.07%
Short Ratio4.42
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.26%
Min EPS beat(2)-15.55%
Max EPS beat(2)38.06%
EPS beat(4)3
Avg EPS beat(4)12.66%
Min EPS beat(4)-15.55%
Max EPS beat(4)38.06%
EPS beat(8)6
Avg EPS beat(8)14.06%
EPS beat(12)10
Avg EPS beat(12)18.21%
EPS beat(16)12
Avg EPS beat(16)14.95%
Revenue beat(2)1
Avg Revenue beat(2)67.39%
Min Revenue beat(2)-100%
Max Revenue beat(2)234.78%
Revenue beat(4)1
Avg Revenue beat(4)-16.3%
Min Revenue beat(4)-100%
Max Revenue beat(4)234.78%
Revenue beat(8)4
Avg Revenue beat(8)148.09%
Revenue beat(12)8
Avg Revenue beat(12)153.87%
Revenue beat(16)12
Avg Revenue beat(16)157.29%
PT rev (1m)-16.3%
PT rev (3m)-14.86%
EPS NQ rev (1m)0.29%
EPS NQ rev (3m)9.72%
EPS NY rev (1m)12.32%
EPS NY rev (3m)12.87%
Revenue NQ rev (1m)-6.66%
Revenue NQ rev (3m)33.34%
Revenue NY rev (1m)250.89%
Revenue NY rev (3m)335.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 86.07
P/FCF N/A
P/OCF N/A
P/B 0.88
P/tB 0.88
EV/EBITDA N/A
EPS(TTM)-1.68
EYN/A
EPS(NY)-2.97
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS0.17
BVpS16.24
TBVpS16.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -9.94%
ROE -10.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-13.05%
ROA(5y)-17.92%
ROE(3y)-14.45%
ROE(5y)-29.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 47.23%
Cap/Sales 9.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 35.86
Quick Ratio 35.86
Altman-Z 10.81
F-Score2
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)293.31%
Cap/Depr(5y)445.07%
Cap/Sales(3y)33.73%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
EPS Next Y-59.85%
EPS Next 2Y-52.28%
EPS Next 3Y-43.94%
EPS Next 5Y-23.31%
Revenue 1Y (TTM)-23.37%
Revenue growth 3Y42.75%
Revenue growth 5YN/A
Sales Q2Q%2177.9%
Revenue Next Year-9.12%
Revenue Next 2Y-64.36%
Revenue Next 3Y-22.51%
Revenue Next 5Y74.85%
EBIT growth 1Y-67.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-62.7%
EBIT Next 3Y-38.69%
EBIT Next 5Y-20.19%
FCF growth 1Y-27.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-33.93%
OCF growth 3YN/A
OCF growth 5YN/A

JANUX THERAPEUTICS INC / JANX FAQ

What is the fundamental rating for JANX stock?

ChartMill assigns a fundamental rating of 4 / 10 to JANX.


What is the valuation status of JANUX THERAPEUTICS INC (JANX) stock?

ChartMill assigns a valuation rating of 0 / 10 to JANUX THERAPEUTICS INC (JANX). This can be considered as Overvalued.


Can you provide the profitability details for JANUX THERAPEUTICS INC?

JANUX THERAPEUTICS INC (JANX) has a profitability rating of 2 / 10.